Look at three more lines on the eye chart after two weeks!

Today, Allergan, a subsidiary of AbbVie, announced that a Phase 3 clinical trial met its primary clinical endpoint: twice-daily use of Vuity eye drops provided sustained relief of presbyopia symptoms

Vuity is an innovative and optimized ophthalmic formulation of pilocarpine whose primary mechanism of action is to constrict the pupil, enhance depth of field, and improve near and intermediate vision

The results announced today come from a Phase 3 clinical trial called VIRGO, which enrolled 230 volunteers, all aged 40-55, with symptoms of presbyopia

In terms of safety, it is similar to the results of the previous once-daily dosing trial, and the main adverse reactions are headache and eye irritation

"We are encouraged by the results of the VIRGO trial, which suggest that twice-daily Vuity may provide presbyopia patients with an additional medication regimen that improves their near vision without affecting their distance vision

References:

[1] Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.